JHVEPhoto/iStock Editorial via Getty Images Pfizer ( PFE ) and Innovent Biologics ( IVBIY ) ( IVBXF ) have entered into a global oncology partnership worth up to $10.5B, underscoring growing demand among multinational drugmakers for innovative therapies developed by Chinese biotech companies. Hong Kong-listed shares of Innovent Biologics surged over +11% on Friday following the announcement. The d...
JHVEPhoto/iStock Editorial via Getty Images Pfizer ( PFE ) and Innovent Biologics ( IVBIY ) ( IVBXF ) have entered into a global oncology partnership worth up to $10.5B, underscoring growing demand among multinational drugmakers for innovative therapies developed by Chinese biotech companies. Hong Kong-listed shares of Innovent Biologics surged over +11% on Friday following the announcement. The deal covers a portfolio of 12 oncology programs, comprising eight Innovent-originated early-stage assets and four Pfizer-proposed discovery programs. The companies will co-develop and share costs for select programs as they advance these programs through clinical development. Under the financial terms of the agreement, Innovent will receive a $650M upfront payment and is eligible for up to $9.85B in development, regulatory, and commercial milestone payments. Additionally, Innovent will receive up to double-digit royalties on sales of each licensed product if approved. For the ‘co-developed, co-commercialized’ programs, the two companies will share the profits in the U.S. and Europe. The transaction is expected to close in the third quarter, subject to fulfillment of required regulatory approvals. “By combining Innovent’s discovery and early clinical development with Pfizer’s global research and development and commercialization capabilities, we have an opportunity not only to strengthen our pipeline, but to accelerate the delivery of breakthroughs that can redefine standards of care,” Jeff Legos, Pfizer’s chief oncology officer, said in the statement . China’s biotech sector is booming, with firms signing overseas licensing deals worth more than $60B in the first quarter. Bristol-Myers Squibb ( BMY ) recently struck a collaboration and licensing deal with Jiangsu Hengrui Pharmaceuticals Co. that could be valued at as much as $15.2B. More on Pfizer, Innovent Biologics Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy FQ1 Healthcare Dividend Round...
Dragon Claws/iStock via Getty Images Global energy markets appear relatively calm on the surface, but that calm may be misleading. Despite the ongoing closure of the Strait of Hormuz, which has reportedly curtailed an estimated 15 to 17 million barrels per day of oil supply and disrupted roughly 20% of global liquefied natural gas flows, crude oil prices have largely remained in the $100 to $120 p...
Dragon Claws/iStock via Getty Images Global energy markets appear relatively calm on the surface, but that calm may be misleading. Despite the ongoing closure of the Strait of Hormuz, which has reportedly curtailed an estimated 15 to 17 million barrels per day of oil supply and disrupted roughly 20% of global liquefied natural gas flows, crude oil prices have largely remained in the $100 to $120 per barrel range. At first glance, markets seem to be treating the crisis as temporary, assuming the strait will reopen soon and global supply will quickly normalize. That assumption may prove dangerously optimistic. The current price stability has not come from a healthy supply-demand balance. Instead, it has been supported by temporary emergency buffers, including coordinated releases from Strategic Petroleum Reserves, the drawdown of floating storage, reduced refinery throughput, and improved inventory management. These measures have delayed the full impact of the supply disruption, but they have not solved it. The central concern is that these buffers are now being exhausted. Analysts estimate that global commercial oil inventories are rapidly falling toward the minimum level required to keep the petroleum system functioning. Once inventories approach that operational floor, the market may no longer be able to absorb the shortage through stockpile drawdowns. At that point, price becomes the primary mechanism for rationing demand. Source: ZeroHedge Why the Market Has Not Fully Reacted Yet When the Strait of Hormuz first closed, the full effect was not immediately visible because of what analysts describe as a “shipping lag.” Tankers that had already departed the Persian Gulf before the closure continued traveling to their destinations. These vessels took several weeks to arrive, which temporarily masked the physical supply loss. By mid-April, however, those last pre-closure cargoes had largely arrived. Since then, ports and refineries have increasingly relied on domestic ...
Earnings Call Insights: Dell Technologies (DELL) Q1 FY 2027 Management View "What a great start to FY '27" (COO & Vice Chairman Jeffrey Clarke) as Dell reported that "demand was stronger than we anticipated across all lines of businesses and geographies" and said customers are "moving decisively to secure supply across a broad range of IT needs." On AI infrastructure, Clarke highlighted the scale ...
Earnings Call Insights: Dell Technologies (DELL) Q1 FY 2027 Management View "What a great start to FY '27" (COO & Vice Chairman Jeffrey Clarke) as Dell reported that "demand was stronger than we anticipated across all lines of businesses and geographies" and said customers are "moving decisively to secure supply across a broad range of IT needs." On AI infrastructure, Clarke highlighted the scale of demand and backlog, saying, "In Q1, we booked $24.4 billion in AI orders and recognized $16.1 billion of AI server revenue" and "exited the quarter with a record $51.3 billion of AI backlog." He added, "Demand continues to exceed supply with memory as the primary constraint, and we expect to exit the year with meaningful backlog." Clarke emphasized portfolio expansion and partner ecosystem around the Dell AI Factory, including announcements spanning NVIDIA’s Vera Rubin platform and enterprise offerings, and said Dell is "expanding the AI factory from the data center to the Deskside" while naming partners such as "NVIDIA, Google Cloud, OpenAI, SpaceX AI, ServiceNow, Palantir, Mistral and CrowdStrike." "Total revenue was up 88% to $43.8 billion" (Chief Financial Officer David Kennedy) and he attributed gross margin rate pressure to AI mix, saying, "Gross margin rate was 18.1%, driven primarily by mix shift to AI servers," while adding, "Excluding the impact of AI mix, gross margin rate was up." Outlook "For Q2, we expect revenue of $44 billion to $45 billion" and "diluted non-GAAP earnings per share is expected to be $4.80, plus or minus $0.10" (CFO Kennedy). He also guided, "ISG is expected to grow roughly 75%, supported by $15.5 billion in AI server revenue, and CSG is expected to be up roughly 20%." "For the full year, we expect revenue of $165 billion to $169 billion" (CFO Kennedy) and "diluted non-GAAP earnings per share is expected to be $17.90, plus or minus $0.25." Kennedy added, "ISG is expected to grow roughly 80%, driven by $60 billion of AI server revenue at th...
Insight with Haslinda Amin, a daily news program featuring in-depth, high-profile interviews and analysis to give viewers the complete picture on the stories that matter. The show features prominent leaders spanning the worlds of business, finance, politics and culture. (Source: Bloomberg)
Insight with Haslinda Amin, a daily news program featuring in-depth, high-profile interviews and analysis to give viewers the complete picture on the stories that matter. The show features prominent leaders spanning the worlds of business, finance, politics and culture. (Source: Bloomberg)
Meta Platforms NASDAQ: META took a real step forward with its artificial intelligence (AI) strategy in April. The company announced the release of its Muse Spark model, helping shares of the tech stock go on a solid run. Meta Platforms Today META Meta Platforms $635.29 +0.03 (+0.00%) 52-Week Range $520.26 ▼ $796.25 Dividend Yield 0.33% P/E Ratio 23.09 Price Target $840.19 Add to Watchlist This was...
Meta Platforms NASDAQ: META took a real step forward with its artificial intelligence (AI) strategy in April. The company announced the release of its Muse Spark model, helping shares of the tech stock go on a solid run. Meta Platforms Today META Meta Platforms $635.29 +0.03 (+0.00%) 52-Week Range $520.26 ▼ $796.25 Dividend Yield 0.33% P/E Ratio 23.09 Price Target $840.19 Add to Watchlist This was for good reason, as key AI evaluation platforms showed that Muse Spark is much more intelligent than Meta’s past Llama models. Get Meta Platforms alerts: Sign Up On the other hand, the Magnificent Seven company has also taken a significant blow when it comes to another AI vertical. Near the end of 2025, Meta announced that it would acquire the AI startup Manus. The deal made a lot of sense, with Manus’s capabilities synergizing well with Meta’s business offerings. However, months later, the Chinese government opted to block the transaction—putting a blemish on Meta’s agentic AI strategy. The Manus Goal: Expanding Meta’s Automated Solutions Manus, once a Chinese company, had quickly built up a large pool of users deploying its agentic AI solutions. This allowed the firm to scale its annual recurring revenue to $100 million just eight months after launching. Manus claimed that this was the fastest pace at which a company had achieved this feat. Manus’s success and the way its technology could improve Meta’s products enticed the company to purchase Manus for over $2 billion. The presumed logic behind the Manus acquisition is relatively straightforward. Advertising drives nearly all of Meta’s revenue, with the company providing various tools to advertisers to support their goals. This includes Advantage+, which uses AI to automate and optimize advertising campaigns. The primary goal of this is to help advertisers get the most business in return for each dollar they spend on Meta. The better the company can do this, the more likely advertisers are to spend money on Meta. Like M...
Twisha's death has made national headlines and has once against brought the issue of dowry deaths into the spotlight. Every year, thousands of women are murdered for bringing in insufficient dowries, even though the practice was banned in 1961.
Twisha's death has made national headlines and has once against brought the issue of dowry deaths into the spotlight. Every year, thousands of women are murdered for bringing in insufficient dowries, even though the practice was banned in 1961.